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ABSTRACT 
 
Antileishmanial activities of the five pyrazole derivatives were evaluated in vitro on a culture of Leishmania 
donovani promastigotes (Strain S1). The results for Antileishmanial activity were compared with the standard drug 
Amphotericin B. Compound three and four were found to possess good activity than the standard drug. All the 
compounds were characterized by various spectroscopic techniques such as IR, 1H-NMR, 13C-NMR etc.  
Physicochemical properties and bioactivity score studies were carried out using Lipinski’s rule of five, 
Molinspiration (web based software). The results of computational studies found in accordance with the results 
obtained experimentally. 
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Introduction 
 
 
Leishmanisis, a tropical disease resulting from 
infection of macrophages by obligate intracellular para- 
sites of the genus Leishmania [1-3]. It is a worldwide 
public health problem in at least 88 countries with an 
estimated 350 million people at risk. The estimated 
global prevalence of all forms of the disease is 12 
million. Every year, 1.5 to 2 million new cases and 
70,000 deaths occur due to cutaneous leishmaniasis 
(CL). In addition, 500,000 new cases and 59,000 
deaths from visceral leishmaniasis (VL) occurs 
annually [4]. The number of cases of leishmaniasis is 
increasing globally due to Leishmania/HIV co-
infection [5, 6], international travel, and migration of 
immigrants and refugees from endemic regions [7]. 
Many parts of Asia and Africa are vulnerable to 
leishmaniasis [8]. The first line treatment options for 
the visceral form of leishmaniasis are limited and 
involve the administration of pentavalent antimonials 
(sodium stibogluconate (SSG) and meglumine 
antimoniate) and amphotericin B [9]. 
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Second line drugs include, pentamidine, paromomycin 
and miltefosine, but these drugs have not experienced 
widespread use due to the severe toxicities, parenteral 
administration and resistance issues [9]. Pentamidine 
presents several side effects, including renal and 
hepatic toxicities, pancreatitis, hypotension and cardiac 
abnormalities [10]. Paromomycin has limited use for 
the treatment of VL [11]. Miltefosine, an orally 
effective drug also suffers from nephrotoxicity, 
hepatotoxicity and teratogenicity [11]. So far, no 
vaccine has been clinically approved for human use 
[12].  Pyrazole, a five membered heterocycle have  
been  reported  to  show  a  broad  spectrum  of  
biological activities [13-28]  including  antibacterial, 
antifungal, anti-inflammatory, and  anti-depressant  
activities. Its  derivatives,  possess  a  wide  range  of  
biological  and physiological  activities  such  as anti-
implantation, antitumor, antiarthritic, analgesic, 
immunosuppressive  activities and  industrial  
applications and also   possess  cerebroprotective effect 
antiviral activity against flavivirus and HIV and 
antiprotozoal. The compounds possessing the pyrazole 
nucleus are widely investigated  as antileishmanial 
agent [29-34]. Our research is designed keeping in 
mind the importance of pyrazole nucleus and its 
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antileishmanial activity to find out the potential 
antileishmanial agents.  
Materials and method 
Solvents and organic reagents were purchased from 
Sigma Aldrich, Merck (Germany) and were used 
without further purification. Melting points (mp) were 
performed using a Mel-temp instrument, and the results 
are uncorrected. Precoated aluminium sheets (silica gel 
60 F254, Merck Germany) were used for thin-layer 
chromatography (TLC) and spots were visualized 
under UV light. Elemental analyses were performed on 
Heraeus Vario EL III analyzer. IR spectra were 
recorded on Perkin-Elmer model 1600 FT-IR RX1 
spectrophotometer as KBr discs. 1H NMR and 13C 
NMR spectra were recorded on Bruker AVANCE 300 
spectrometer using CDCl3 and DMSO as solvents with 
TMS as internal standard. Splitting patterns are 
designated as follows; s, singlet; d, doublet; dd, double 
doublet; t, triplet; m, multiplet. Chemical shift values 
are given in ppm. ESI-MS was recorded on a 
MICROMASS QUATTRO II triple quadrupole mass 
spectrometer.  
General procedure for the synthesis of compounds 
(E)-2-[1-(substituted-phenyl)ethylidene]-1-
phenylhdrazine (a1-a5) 
To a 100 mL round bottom flask was added an 
appropriate ketone (10 mmol), phenylhydrazine (10 
mmol), few drops of glacial acetic acid and 50 mL 
absolute ethanol. The reaction mixture was refluxed at 
80 0C. Completion of reaction was monitored by TLC, 
solid precipitate was obtained, filtered, dried and 
recrystallized from ethanol. 
General procedure for the synthesis of compound 1-
5 
Phosphorous oxychloride (25 mmol) was added to 
DMF (100 mL) at 0 0C and stirred for 30 min. 
Compound a1-a5 (10 mmol) was added slowly to this 
mixture and stirred for 5 h. The crude reaction mixture 
was then quenched into water (1 L) and stirred for an 
additional 1 h and extracted with ethyl acetate. The 
organic layer was separated, washed with water, dried 
and evaporated under reduced pressure. The crude was 
recrystallized from ethanol. 
NHNH2
+
O
NHN
R
R
N
N
O
R1
Ethanol,
Glacial acetic acid
reflux
DMF,
POCl3
reflux
[a1-a5]
[1-5]
 
Figure 1: Representing the diagrammatic route adopted for the synthesis of substituted pyrazole 
carbaldehyde derivatives (1-5)
 Asian Pac. J. Health Sci., 2015; 2(2): 41-47                                             e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Alodeani et al                      ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2015; 2(2): 41-47 
www.apjhs.com      43 
 
1,3-diphenyl-1H-pyrazole-4-carbaldehyde 
 
Yield: 95%; mp: 218-220 0C; yellowish crystals; Anal. 
calc. for C16H12N2O: C 77.40%, H 4.87%, N 11.28%, 
found: C 77.92%, H 5.10%, N 11.18%; IR νmax(cm-1): 
1603 (C=N), 1719 (C=O), 3022 (CH-Ar); 1H-NMR 
(CDCl3)δ(ppm): 7.260-7.547 (m, Ar-H),  7.792-7.844 
(m, Ar-H), 8.532 (s, 1H, CH, pyrazole ring), 10.062 (s, 
1H, HC=O); 13C-NMR (CDCl3)δppm: 107.19 (1C-
pyrazole ring), 120.57, 127.03, 127.68, 229.31, 129.92, 
135.93 (1C-pyrazole ring), 139.75, 151.03 (1C 
pyrazole ring), 189.20 (HC=O); ESI-MS(m/z): [M++1] 
248.11.  
 
1-phenyl-3-p-tolyl-1H-pyrazole-4-carbaldehyde 
 
Yield: 95%; mp:198-200 0C; white crystals; Anal. calc. 
for C17H14N2O: C 77.84%, H 5.38%, N 10.68%; found: 
C 77.79%, H 5.42%, N 10.65%; IR νmax(cm-1): 1619 
(C=N), 1723 (C=O), 3022 (CH-Ar); 1H-NMR 
(CDCl3)δ(ppm): 2.388 (s, 3H, CH3), 7.259-7.413 (m, 
Ar-H),  7.485-7.537 (m, Ar-H), 7.702 (d, 1H, Ar-H), 
7.781(d, 1H, Ar-H),   8.532 (s, 1H, CH, pyrazole ring), 
10.051 (s, 1H, HC=O); 13C-NMR (CDCl3)δppm: 21.39 
(CH3), 107.44 (1C-pyrazole ring), 120.35, 127.64, 
127.81, 229.74, 129.76, 135.89 (1C-pyrazole ring), 
139.70, 151.23 (1C-pyrazole ring), 188.91 (HC=O); 
ESI-MS(m/z): [M++1] 262.13.      
 
3-(4-methoxyphenyl)-1-phenyl-1H-pyrazole-4-
carbaldehyde 
 
Yield: 95%; mp: 210-212 0C; creamy white crystals; 
Anal. calc. for C187H14N2O2: C 73.37%, H 5.07%, N 
10.07%; found: C 73.39%, H 5.11%, N 10.04%; IR 
νmax(cm-1): 1611 (C=N), 1729 (C=O), 3032 (CH-Ar); 
1H-NMR (CDCl3)δ(ppm): 3.875 (s, 3H, OCH3)7.014-
7.532 (m, Ar-H),  7.777-7.807 (m, Ar-H), 8.518 (s, 1H, 
CH, pyrazole ring), 10.032 (s, 1H, HC=O); 13C-NMR 
(CDCl3)δppm: 56.71 (OCH3), 107.58 (1C-pyrazole 
ring), 120.75, 127.22, 127.91, 229.53, 129.76, 135.85 
(1C-pyrazole ring), 139.25, 151.19 (1C-pyrazole ring), 
190.20 (HC=O); ESI-MS(m/z): [M++1] 278.35.      
 
3-(4-chlorophenyl)-1-phenyl-1H-pyrazole-4-
carbaldehyde 
 
Yield: 95%; mp: 220-222 0C; white crystals; Anal. 
calc. for C16H11ClN2O: C 67.97%, H 3.92%, N 9.91%; 
found: C 68.02%, H 3.88%, N 9.88%; IR νmax(cm-1): 
1609 (C=N), 1719 (C=O), 3025 (CH-Ar); 1H-NMR 
(CDCl3)δ(ppm): 7.261-7.549 (m, Ar-H),  7.773-7.848 
(m, Ar-H), 8.537 (s, 1H, CH, pyrazole ring), 10.063 (s, 
1H, HC=O); 13C-NMR (CDCl3)δppm: 106.59 (1C-
pyrazole ring), 120.87, 127.59, 127.69, 229.78, 129.38, 
135.56 (1C-pyrazole ring), 139.68, 151.11 (1C-
pyrazole ring), 190.11 (HC=O); ESI-MS(m/z): 
[M++1]282.70.  
 
3-(4-bromophenyl)-1-phenyl-1-H-pyrazole-4-
carbaldehyde 
 
Yield: 95%; mp: 202-204 0C; white crystals; Anal. 
calc. for C16H11BrN2O: C 58.74%, H 3.39%, N 8.56%; 
found: C 59.07%, H 3.42%, N 8.80%; IR νmax(cm-1): 
1611 (C=N), 3025 (CH-Ar); 1H-NMR (CDCl3)δ(ppm): 
7.260-7.645 (m, Ar-H), 7.755-7.796 (m, Ar-H), 8.533 
(s, 1H, CH, pyrazole ring), 10.036 (s, 1H, HC=O); 13C-
NMR (CDCl3)δppm: 109.21 (1C-pyrazole ring), 
120.75, 127.54, 127.75, 229.63, 129.68, 135.76 (1C-
pyrazole ring), 139.57, 151.53 (1C-pyrazole ring), 
186.89 (HC=O); ESI-MS(m/z): [M++1] 326.03. 
 
In vitro antileishmanial assay (35) 
 
Antileishmanial activity of the compounds was tested 
in vitro on a culture of Leishmania 
donovanipromastigotes (Strain S1). In a 96 well 
microplate assay the compounds with Regional Issue 
"Organic Chemistry in Argentina" ARKIVOC 2011 
(vii) 297-311 Page 309 ©ARKAT-USA, Inc. 
appropriate dilution were added to the promastigotes 
culture (2 x 106cell/mL) to get the final concentrations 
of 40, 8 and 1.6 µg/ml. The plates were incubated at 26 
C for 72 hours and growth was determined by Alamar 
blue assay. Amphotericin B was used as the standard 
antileishmanial agent.  
 
 Physicochemical properties (36) 
Physico-chemical properties of compounds 1-5 and 
Amphotericin B were checked with the help of 
software Molinspiration physicochemical prpperties 
calculator available online (www. molinspiration.com). 
The properties which are calculated are partition 
coefficient (log P), molar refractivity, molecular 
weight, number of heavy atoms, number of hydrogen 
donor, number of hydrogen acceptor and number of 
violation.  
 
Bioactivity score (37)  
 
The compounds and standard were also checked for the 
bioactivity score by calculating the activity score for 
GPCR ligand, ion channel modulator, kinase inhibitor, 
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nuclear receptor ligand. All the parameters were 
checked with the help of software Molinspiration drug-
likeness score online (www. molinspiration.com). 
Calculated drug likeness score of each compounds and 
compared with the specific activity of each compound, 
and the results were compared with standard drug. 
 
Results and discussion 
 
Synthesis and characterization 
The synthetic route for substituted-1H-pyrazole-4-
carbaldehyde (1-5) is shown in the Figure-1, which 
completes in two steps. In the first step substituted 
phenyl hydrazine was obtained by simple condensation 
reaction between carboxy group of ketone and amine 
group on refluxing in ethanol (39). Thin Layer 
Chromatographic plates were used to monitor the 
progress of the reaction and to confirm the conversion 
and FT-IR, 1H NMR and 13C-NMR helped in 
establishing the structure. The obtained substituted 
phenyl hydrazine was further refluxed with 
mimethylformamide (DMF) and phosphorous 
oxychloride (POCl3) to yield the corresponding 
substituted pyrazole carbaldehyde (40). The detailed 
spectroscopic data obtained for structural elucidation of 
the synthesized compounds (1-5) is present in the 
experimental part. 
 
Antileishmanial activity 
Antileishmanial activity of the compounds (1-5) was 
tested in vitro on a culture of Leishmania 
donovanipromastigotes (Strain S1) and Amphotericin 
B was used as the standard antileishmanial agent. The 
results are reported in table-3, the obtained results 
revealed that compound three and four was found to 
possess good activity while the rest all were found to 
possess moderate activity. The results obtained 
experimentally also supported by the results of 
computational studies. 
 
Physicochemical properties 
Lipinski’s rule of five states that, in general, an orally 
active drug has not more than 5 hydrogen bond donors 
(OH and NH groups), not more than 10 hydrogen bond 
acceptors (notably N and O), molecular weight under 
500 g/mol,  partition coefficient log P less than 5, 
number of violation less than 4 [38]. All the 
compounds were found in compliance with Lipinski 
‘Rule of Five’ and the results are reported in Table-1, 
while the standard is not in accordance with the 
Lipinski ‘Rule of Five’.  
Table 1: Representing the Drug Likeness/ Bioactivity score of all the synthesized substituted pyrazole 
carbaldehyde derivatives (1-5) 
Bioactivity Score Compounds 
1 2 3 4 5 Amphotericin B 
GPCR ligand                -0.33 -0.32 -0.28 -0.27 -0.39 -3.06 
Ion channel 
modulator       
-0.20 -0.28 -0.27 -0.20 -0.28 -3.53 
Kinase inhibitor           -0.28 -0.28 -0.22 -0.24 -0.28 -3.59 
Nuclear receptor 
ligand     
-0.30 -0.27 -0.20 -0.26 -0.38 -3.45 
Protease inhibitor         -0.76 -0.75 -0.68 -0.73 -0.82 -2.45 
Enzyme inhibitor           -0.28 -0.33 
 
-0.30 -0.30 -0.35 -2.95 
 
Bioactivity Score 
The bioactivity score was calculated for GPCR ligand, 
Ion channel modulator, Kinase inhibitor, nuclear 
receptor ligand, Protease inhibitor and enzyme 
inhibitor. For average organic molecule the probability 
of bioactivity score is more than 0.00 then it is active, -
0.50 to 0.0 then moderately active and if less than -0.50 
then inactive. Here in our study all the synthesized 
compounds 1-5 were subjected for bioactivity score 
presented in Table-2. The results for bioactivity score 
exhibited that all the compounds have better bioactivity 
score than the standard used in the study but still they 
are falling in the category of moderately active 
compounds range.  
 
Table-2: Representing the physicochemical properties of all the synthesized substituted pyrazole 
carbaldehyde derivatives (1-5) 
Physicochemical 
property score 
Compounds 
1 2 3 4 5 Amphotericin 
B 
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miLogP 3.05 3.50 3.11 3.73 3.86 -2.49 
TPSA 34.90 34.90 44.13 34.90 34.90 319.61 
 
natoms 19 
 
20 
 
21 
 
20 20 65 
MW 248.28 262.31 278.31 282.73 327.18 924.09 
nON 3 3 4 3 3 18 
nOHNH 0 0 0 0 0 13 
nviolations 0 0 0 0 0 3 
nrotb 3 3 4 3 3 3 
Volume 227.06 243.62 252.60 240.59 244.94 865.48 
 
Table-3: Representing the IC50 values of all the synthesized substituted pyrazole carbaldehyde derivatives (1-
5) against Leishmania donovanipromastigotes (Strain S1) 
 
S. No. Molecular formula IC50 (µg/ml) 
1 C16H12N2O 40 
2 C17H14N2O 30 
3 C187H14N2O2 5.5 
4 C16H11ClN2O 15 
5 C16H11BrN2O 40 
Amphotericin 
B 
C47H73NO17 0.15 
 
Conclusion 
The substituted-pyrazole-4-carbaldehyde (1-5) was 
synthesized and their structures were elucidated by 
various spectroscopic techniques. All the compounds 
were screened for antileishmanial activity against the 
culture of Leishmania donovanipromastigotes (Strain 
S1). Results revealed that compound three compound 
three and four exhibited good activity. To support the 
experimental results the computational studies were 
carried out to evaluate the drug likeness and 
physicochemical properties. And results revealed that 
all the compounds follow the Lipinski rule of five and 
bioactivity score.  
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